Form 144 - Report of proposed sale of securities:
SEC Accession No. 0000947871-24-000493
Filing Date
2024-05-17
Accepted
2024-05-17 15:11:45
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 2952
  Complete submission text file 0000947871-24-000493.txt   4682
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED CAPITAL LLC (Reporting) CIK: 0001157524 (see all company filings)

EIN.: 134133323 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144

Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Subject) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39247 | Film No.: 24959197
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)